Compare
Utah Medical Products Inc vs Iradimed Corp vs Lemaitre Vascular Inc vs Embecta Corp.
| Latest fiscal year | Utah Medical Products Inc UTMD | Iradimed Corp IRMD | Lemaitre Vascular Inc LMAT | Embecta Corp. EMBC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $38.52M | $83.81M | $249.60M | $1.08B |
| Revenue growth (YoY) | -5.8% | +14.4% | +13.5% | -3.8% |
| Gross margin | 57.1% | 76.7% | 71.5% | 62.6% |
| Operating margin | 29.6% | 31.2% | 27.2% | 22.4% |
| Net margin | 29.3% | 26.8% | 23.1% | 8.8% |
| Net income | $11.29M | $22.48M | $57.73M | $95.40M |
| EPS (Diluted) | $3.48 | $1.75 | $2.52 | $1.62 |
| Operating cash flow | $14.69M | $24.95M | $81.25M | $191.70M |
| Free cash flow | $14.32M | $17.18M | $74.47M | $182.40M |
| Cash & equivalents | $85.76M | $51.16M | $28.24M | $225.50M |
| Total assets | $122.54M | $108.78M | $615.69M | $1.09B |
| Total liabilities | $3.27M | $14.16M | $222.17M | n/a |
| Shareholders' equity | $119.27M | $94.62M | $393.52M | -$650.60M |
| Return on year-end equity | 9.5% | 23.8% | 14.7% | n/a |
| Shares outstanding | 3.19M | 12.78M | 22.77M | 58.50M |
Revenue, most recent five fiscal years
| Fiscal year | Utah Medical Products Inc | Iradimed Corp | Lemaitre Vascular Inc | Embecta Corp. |
|---|---|---|---|---|
| Latest | $38.52M Ended 2025-12-31 | $83.81M Ended 2025-12-31 | $249.60M Ended 2025-12-31 | $1.08B Ended 2025-09-30 |
| 1 year earlier | $40.90M Ended 2024-12-31 | $73.24M Ended 2024-12-31 | $219.86M Ended 2024-12-31 | $1.12B Ended 2024-09-30 |
| 2 years earlier | $50.22M Ended 2023-12-31 | $65.56M Ended 2023-12-31 | $193.48M Ended 2023-12-31 | $1.12B Ended 2023-09-30 |
| 3 years earlier | $52.28M Ended 2022-12-31 | $53.30M Ended 2022-12-31 | $161.65M Ended 2022-12-31 | $1.13B Ended 2022-09-30 |
| 4 years earlier | $49.05M Ended 2021-12-31 | $41.81M Ended 2021-12-31 | $154.42M Ended 2021-12-31 | $1.17B Ended 2021-09-30 |